Published • loading... • Updated
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
- DualityBio and Genentech have entered a global collaboration to develop next-generation antibody-drug conjugates using DualityBio's DUPAC platform that focuses on novel payload mechanisms of action.
- DualityBio will lead discovery and early clinical development of ADCs targeting oncology proteins specified by Genentech, while Genentech will have exclusive rights for further clinical development and commercialization after Phase 1a.
- Genentech receives an exclusive worldwide license to the collaboration ADCs, and DualityBio will receive an upfront payment of $45 million plus potential milestone payments exceeding $1 billion along with tiered royalties on approved product sales.
- DualityBio identified an unmet medical need for patients with tumors resistant or refractory to topoisomerase inhibitor-based ADCs, which have achieved broad clinical success.
Insights by Ground AI
40 Articles
40 Articles
The Logan Banner+39 Reposted by 39 other sources
DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercializationDUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises multiple payloads with novel mechanism of action designed…
Coverage Details
Total News Sources40
Leaning Left4Leaning Right3Center26Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
12%
C 79%
Factuality
To view factuality data please Upgrade to Premium
